Core Viewpoint - Yuekang Pharmaceutical emphasizes the philosophy that "the quality of medicine must be perfect; ninety-nine points equal zero," which is integral to its operations from research and development to production [1][4]. Group 1: Company Development - Yuekang Pharmaceutical started in 2001 in Beijing and has grown to be among the top 100 pharmaceutical companies in China, successfully listing on the Sci-Tech Innovation Board [1]. - The company aims to provide affordable quality medicine, overcoming challenges posed by imported drug monopolies and inconsistent drug quality in the market [1]. Group 2: Innovation and Quality Control - Yuekang has established a comprehensive quality system guided by clinical value, including a project for a national class innovative drug, which involves setting quality grading standards for medicinal materials [1]. - The company’s flagship product, Huoxin Wan, has undergone extensive clinical validation, showcasing a commitment to stringent raw material selection and post-market research [1]. Group 3: Production Standards - The production process for products like Omeprazole enteric-coated capsules involves over 200 inspections, ensuring high-quality standards that exceed national benchmarks [2]. - Yuekang has achieved certifications such as EU GMP and Japan JGMP, aligning its production standards with international practices and earning the title of "Quality Benchmark" in 2017 [2]. Group 4: Industry Positioning - Yuekang Pharmaceutical connects every node of the pharmaceutical supply chain through its commitment to quality, positioning itself as a pioneer in the international innovative pharmaceutical market [4].

Core Viewpoint - The company, Yuyuan Pharmaceutical Group, is leveraging quality, innovation, and digitalization as its three core driving forces to achieve differentiated high-quality development in the rapidly transforming global biopharmaceutical industry [1]. Group 1: Quality - Quality is the lifeline of Yuyuan Pharmaceutical's development, exemplified by the introduction of new high-end excipients in the production of Metformin sustained-release tablets, which significantly reduced the size of the medication while ensuring efficacy and lowering material consumption [3]. - The "process innovation + quality upgrade" model has been successfully replicated in core products such as Huoxin Pill and Omeprazole enteric-coated capsules, creating a virtuous cycle of "quality improvement - market expansion - R&D iteration" [3]. Group 2: Innovation - The company maintains a high level of R&D investment, with 2024 R&D expenditure reaching 422 million yuan, accounting for 11.16% of its operating revenue [3]. - Yuyuan Pharmaceutical has achieved significant results from its continuous innovation efforts, with 63 new patent authorizations in the year, bringing the total to 317 patents [3]. - The company has broken new ground in various therapeutic areas, including the domestic ED treatment market with its drug Ailisi (Citrus Aidenafil) and advancements in traditional Chinese medicine with Hydroxy Safflower Yellow A for injection [3]. Group 3: Digitalization - Yuyuan Pharmaceutical is actively embracing digital transformation through a comprehensive strategic partnership with Huawei, focusing on building an AI drug development platform that integrates AI algorithms into all stages of drug development [4]. - The company has secured over 10 authorized patents in the field of AI drug development and published two research papers in internationally recognized journals [4]. - The AI-designed innovative drug YKYY018 has garnered significant attention within the industry, showcasing its strong innovative potential [4]. Group 4: Future Outlook - By establishing a composite development system of "quality foundation, innovation-driven, digital support," Yuyuan Pharmaceutical provides valuable insights for biopharmaceutical companies exploring new productive forces [6]. - With its unique competitive advantages, the company is expected to continue making breakthroughs in the global biopharmaceutical market, injecting new vitality into the industry's high-quality development [6].

Core Insights - Recently, Yuyuan Pharmaceutical achieved a breakthrough in new drug development with its mRNA vaccine YKYY025 for respiratory syncytial virus (RSV) receiving clinical trial approval from the National Medical Products Administration (NMPA) in China, following prior approval from the FDA in the United States, showcasing the company's strong innovation capabilities and international competitiveness [1][3] Group 1: Innovation in mRNA Vaccine Development - Yuyuan Pharmaceutical's subsidiary, Hangzhou Tianlong Pharmaceutical, has successfully submitted clinical trial applications for multiple mRNA vaccines, including YKYY026 for shingles, which has also been accepted by the NMPA [3] - The company has received clinical approvals for its broad-spectrum anti-coronavirus peptide YKYY017 aerosol inhalation and long-acting lipid-lowering nucleic acid drug YKYY015 in both China and the U.S. [3] - Yuyuan's proprietary nucleic acid delivery system has been granted patents in multiple countries, including the U.S., Japan, and Israel, establishing a solid foundation for its mRNA vaccine and nucleic acid drug development [3] Group 2: Comprehensive R&D Platform - The company has built a complete platform system for nucleic acid drug development, covering target discovery, high-throughput screening, process development, and quality control, which is rare among domestic pharmaceutical companies [4] - Yuyuan Pharmaceutical has multiple innovative products nearing commercialization, with three class 1 innovative drugs receiving acceptance for market application, and its peptide drug YKYY017 entering phase III clinical trials [4] - The anti-liver cancer antisense oligonucleotide drug CT102 has completed phase IIa clinical trials, indicating a strong pipeline that could provide new treatment options for patients and drive future growth for the company [4]

证券代码：688658 证券简称：悦康药业 公告编号：2025-022 悦康药业集团股份有限公司 第二届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 悦康药业集团股份有限公司（以下简称"公司"）第二届监事会第十七次会 议于 2025 年 4 月 28 日在公司会议室召开。本次会议由监事会主席滕秀梅召集 和主持，会议应出席监事 3 人，实际出席监事 3 人。本次会议的召开及表决程 序符合《中华人民共和国公司法》及《悦康药业集团股份有限公司章程》（以下 简称"《公司章程》"）的规定。 二、监事会会议审议情况 （一）审议通过《关于公司<2025 年第一季度报告>的议案》 监事会认为：公司 2025 年第一季度报告编制和审议程序符合法律法规、 《公司章程》和公司内部管理制度的各项规定，报告内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏，客观地反映了公司 2025 年第 一季度财务及经营状况。 表决结果：同意票 3 票、反对票 0 票、弃权票 0 票。 具体内 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-023 悦康药业集团股份有限公司 关于 2025 年第一季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1-1 对于存在客观证据表明存在减值，以及其他适用于单项评估的应收票据、 应收账款，其他应收款、应收款项融资等单独进行减值测试，确认预期信用损 失，计提单项减值准备。对于不存在减值客观证据的应收票据、应收账款、其 他应收款、应收款项融资或当单项金融资产无法以合理成本评估预期信用损失 的信息时，本公司依据信用风险特征将应收票据、应收账款、其他应收款、应 收款项融资等划分为若干组合，在组合基础上计算预期信用损失。 经测试，2025 年第一季度计提信用减值损失金额共计-1,226,553.19 元。 悦康药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第二届董事会第十九次会议、第二届监事会第十七次会议，分别审议通过了 《关于 2025 年第一季度计提资产减值准备的议案》。现将相关事项公告如下： 一、计提资 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-025 悦康药业集团股份有限公司 自愿披露关于注射用更昔洛韦 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 剂型：注射剂 规格：0.5g 注册分类：化学药品 原药品批准文号：国药准字 H20053671 上市许可持有人：悦康药业集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44 号）、《关于仿制药质量和疗 效一致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药监局关于 开展化学药品注射剂仿制药质量和疗效一致性评价工作的公告》（2020 年第 62 号）的规定，经审查，本品符合药品注册的有关要求，批准本品增加 0.5g 规格 的补充申请，核发药品批准文号，本品通过仿制药质量和疗效一致性评价。 二、药品的相关信息 注射用更昔洛韦主要用于治疗危及生命或视觉的免疫缺陷患者的巨细胞病 毒感染，以及预防器官移植病人的巨细胞病毒感染。 近日，悦 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-024 悦康药业集团股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 16 日（星期五）9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 公司已于 2025 年 4 月 29 日发布公司《2025 年第一季度报告》，为便于广大 投资者更全面深入地了解公司 2025 年第一季度经营成果、财务状况，公司计划 于 2025 年 5 月 16 日（星期五）9:00-10:00 举行 2025 年第一季度业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第一季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允 ...

Financial Performance - The company's revenue for Q1 2025 was ¥577,383,322.42, representing a decrease of 40.35% compared to ¥967,900,022.68 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥49,271,134.83, a decline of 171.09% from a profit of ¥69,305,423.83 in the previous year[4] - The net cash flow from operating activities decreased by 44.54%, amounting to ¥81,041,633.19 compared to ¥146,130,897.27 in the prior year[4] - Total operating revenue for Q1 2025 was ¥577.38 million, a decrease of 40.4% compared to ¥967.90 million in Q1 2024[17] - Net profit for Q1 2025 was a loss of ¥49.50 million, compared to a profit of ¥69.12 million in Q1 2024, indicating a significant decline[18] - Operating profit for Q1 2025 was a loss of ¥58.45 million, contrasting with a profit of ¥80.36 million in Q1 2024[17] - Cash flow from operating activities for Q1 2025 was ¥81.04 million, down 44.5% from ¥146.13 million in Q1 2024[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,611,332,242.14, a decrease of 2.21% from ¥5,738,112,424.72 at the end of the previous year[5] - The company's current assets totaled RMB 3,037,807,721.74, down from RMB 3,157,931,976.13, indicating a decrease of about 3.8%[12] - Cash and cash equivalents increased to RMB 1,454,983,942.63 from RMB 1,331,795,660.80, representing a growth of approximately 9.2%[12] - Inventory decreased significantly from RMB 757,335,702.72 to RMB 645,468,495.43, a reduction of around 14.7%[12] - Total liabilities decreased from RMB 2,153,155,749.09 to RMB 2,075,873,810.65, a decline of about 3.6%[14] - The company's equity attributable to shareholders decreased from RMB 3,577,629,966.77 to RMB 3,528,358,831.94, a decrease of approximately 1.4%[14] - The company reported a short-term loan of RMB 103,133,365.43, down from RMB 112,965,265.65, reflecting a decrease of about 8.0%[14] - The company's accounts receivable stood at RMB 575,284,268.66, a slight decrease from RMB 611,698,533.96, indicating a reduction of approximately 6.0%[12] - The company's total non-current assets were RMB 2,573,524,520.40, slightly down from RMB 2,580,180,448.59, reflecting a decrease of about 0.3%[13] Research and Development - Research and development expenses totaled ¥99,271,226.53, which is an increase of 2.27% year-over-year, and accounted for 17.19% of total revenue, up by 10.03 percentage points[5] - The company is actively promoting and increasing investment in key R&D projects, including small nucleic acid drugs and peptide drugs, to maintain industry leadership[7] - Research and development expenses for Q1 2025 were ¥97.17 million, an increase of 13.6% from ¥85.50 million in Q1 2024[17] Sales and Marketing - The company plans to optimize sales strategies and maintain core sales channels to address the decline in revenue and profit[7] - Sales expenses for Q1 2025 were ¥130.66 million, down 55.6% from ¥294.03 million in Q1 2024[17] Financial Metrics - The weighted average return on equity was -1.39%, down by 3.31 percentage points from 1.92% in the previous year[4] - The basic and diluted earnings per share were both -¥0.11, a decrease of 173.33% from ¥0.15 in the same period last year[4] - The company incurred a financial expense of ¥3.61 million in Q1 2025, compared to a financial income of ¥0.54 million in Q1 2024[17]

Financial Performance - The company reported a basic earnings per share of -0.1100 yuan for Q1 2025, a decrease of 173.33% compared to 0.1500 yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 5.77 billion yuan, down 40.39% from 9.68 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.49 billion yuan, representing a decline of 171.01% from a profit of 0.69 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -1.39%, a significant drop from 1.92% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 25,836.88 million shares, accounting for 57.42% of the circulating shares, with a decrease of 1,485.70 million shares compared to the previous period [1] - The largest shareholder, Fuyang Jingyue Yongshun Information Consulting Co., Ltd., holds 18,024.01 million shares, representing 40.05% of the total share capital, with no change [2] - Hong Kong Central Clearing Limited and China Merchants Medical Health Industry Stock have exited the top ten shareholders list [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 悦康药业集团股份有限公司（以下简称"公司"或"悦康药业"）控股股东 阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持有公司股份 180,240,120 股，占公司总股本的比例为 40.05%。截至本公告披露日，本次京悦 永顺持有的本公司 26,500,000 股无限售流通股股票将被司法拍卖。 目前拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行法定 程序、股权变更过户等环节，存在一定的不确定性。公司将根据最终结果，依法 履行相应的信息披露义务。 拍卖成交后，买受人后续减持股票需符合《上市公司股东减持股份管理 暂行办法》及《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、 高级管理人员减持股份（2025 年 3 月修订）》等相关规定。同时买受人还需遵守 中国证监会、上海证券交易所等关于上市公司信息披露的相关规定，依法履行信 息披露义务。股票后续能否立即在二级市场进行交易，具体的情况应以监管部门 的认定为准。 京悦永顺持有的部分本公司股份 ...